Immune effector cell-associated neurotoxicity syndrome, grade 2
ICD-10 G92.02 is a billable code used to indicate a diagnosis of immune effector cell-associated neurotoxicity syndrome, grade 2.
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological complication that can occur following immunotherapy, particularly with CAR T-cell therapy. Grade 2 ICANS is characterized by moderate neurological symptoms that may include confusion, lethargy, and mild motor deficits. Patients may experience pain syndromes, such as headaches or neuropathic pain, as well as autonomic disorders that can manifest as fluctuations in heart rate and blood pressure. Hydrocephalus may also develop due to increased intracranial pressure, leading to further neurological impairment. The syndrome is a result of the immune system's response to the tumor and the therapy, which can lead to inflammation and neurotoxicity. Diagnosis is based on clinical evaluation and the exclusion of other causes of neurological symptoms. Management typically involves supportive care and may include corticosteroids to reduce inflammation. Understanding the nuances of ICANS is crucial for accurate coding and appropriate patient management.
Detailed records of immunotherapy treatments, patient symptoms, and neurological evaluations.
Patients receiving CAR T-cell therapy presenting with neurological symptoms.
Close monitoring of neurological status and timely documentation of any changes.
Comprehensive neurological assessments and imaging studies to rule out other causes.
Patients with new-onset neurological symptoms post-immunotherapy.
Differentiating ICANS from other neurological disorders is critical for accurate coding.
Used when administering CAR T-cell therapy.
Document the type of therapy, dosage, and patient response.
Oncology specialists must ensure accurate coding of therapy related to ICANS.
Common symptoms include confusion, lethargy, mild motor deficits, and autonomic instability. Patients may also experience headaches and other pain syndromes.
